Strativa's Zuplenz receives FDA approval

WOODCLIFF LAKE, N.J. The Food and Drug Administration has approved a preventive treatment made by Strativa Pharmaceuticals for nausea resulting from chemotherapy and radiotherapy, Strativa said Friday.

The FDA approved Zuplenz (ondansetron) oral-soluble film for preventing postoperative, highly and moderately emetogenic cancer chemotherapy-induced and radiotherapy-induced nausea and vomiting. The drug uses MonoSol Rx’s proprietary PharmFilm technology, which allows the film to rapidly dissolve on the tongue without the aid of water.

“The FDA approval of Zuplenz marks an important milestone for Strativa as it reinforces our commitment to enhancing prescription products to meet the different needs of patients,” Strativa president John MacPhee said. “Zuplenz offers an innovative and convenient, easy-to-take formulation for patients who have trouble swallowing tablets, while providing the trusted efficacy expected from ondasetron.”